Influenza vaccination for older adults

Talbot, H. Keipp; Libster, Romina; Edwards, Kathryn M.

doi:10.4161/hv.8.1.18129

Cited by 9 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A gradual decrement in the HI antibody GMTs elicited by both study vaccines against the A(H1N1)pdm09 vaccine strain in older subjects was observed and this could be attributed to "immunosenescence" [47,48]. A decreasing trend with advancing age was also observed in the frequency of solicited adverse events.…”

Section: Discussionmentioning

confidence: 81%

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial

Yang¹,

Dionne²,

Kyle³

et al. 2013

Vaccine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 81%

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial

Yang¹,

Dionne²,

Kyle³

et al. 2013

Vaccine

View full text Add to dashboard Cite

show abstract

“…This review examines the evidence for current best use of vaccines against influenza, pneumococcal disease, and herpes zoster in adults of 60 and older, and identifies evidence gaps and potential directions for future research. Functional status (frailty) predisposes to infectious risk and vaccine responsiveness and may be more important than chronological age 4…”

Section: Introductionmentioning

confidence: 99%

Vaccines for older adults

Cunningham

McIntyre

Subbarao

et al. 2021

BMJ

View full text Add to dashboard Cite

The proportion of the global population aged 65 and older is rapidly increasing. Infections in this age group, most recently with SARS-CoV-2, cause substantial morbidity and mortality. Major improvements have been made in vaccines for older people, either through the addition of novel adjuvants—as in the new recombinant zoster vaccine and an adjuvanted influenza vaccine—or by increasing antigen concentration, as in influenza vaccines. In this article we review improvements in immunization for the three most important vaccine preventable diseases of aging. The recombinant zoster vaccine has an efficacy of 90% that is minimally affected by the age of the person being vaccinated and persists for more than four years. Increasing antigen dose or inclusion of adjuvant has improved the immunogenicity of influenza vaccines in older adults, although the relative effectiveness of the enhanced influenza vaccines and the durability of the immune response are the focus of ongoing clinical trials. Conjugate and polysaccharide pneumococcal vaccines have similar efficacy against invasive pneumococcal disease and pneumococcal pneumonia caused by vaccine serotypes in older adults. Their relative value varies by setting, depending on the prevalence of vaccine serotypes, largely related to conjugate vaccine coverage in children. Improved efficacy will increase public confidence and uptake of these vaccines. Co-administration of these vaccines is feasible and important for maximal uptake in older people. Development of new vaccine platforms has accelerated following the arrival of SARS-CoV-2, and will likely result in new vaccines against other pathogens in the future.

show abstract

“…It has been suggested that the effectiveness of vaccines in the population is affected by several factors such as age [2] , malnutrition [3] , and concurrent infections [4] – [9] . One of the factors that could potentially affect HIV vaccination efficacy is high prevalence of tuberculosis (TB) in HIV endemic regions.…”

Section: Introductionmentioning

confidence: 99%

Mycobacterium tuberculosis Infection Interferes with HIV Vaccination in Mice

et al. 2012

View full text Add to dashboard Cite

Tuberculosis (TB) has emerged as the most prominent bacterial disease found in human immunodeficiency virus (HIV)-positive individuals worldwide. Due to high prevalence of asymptomatic Mycobacterium tuberculosis (Mtb) infections, the future HIV vaccine in areas highly endemic for TB will often be administrated to individuals with an ongoing Mtb infection. The impact of concurrent Mtb infection on the immunogenicity of a HIV vaccine candidate, MultiHIV DNA/protein, was investigated in mice. We found that, depending on the vaccination route, mice infected with Mtb before the administration of the HIV vaccine showed impairment in both the magnitude and the quality of antibody and T cell responses to the vaccine components p24Gag and gp160Env. Mice infected with Mtb prior to intranasal HIV vaccination exhibited reduced p24Gag-specific serum IgG and IgA, and suppressed gp160Env-specific serum IgG as compared to respective titers in uninfected HIV-vaccinated controls. Importantly, in Mtb-infected mice that were HIV-vaccinated by the intramuscular route the virus neutralizing activity in serum was significantly decreased, relative to uninfected counterparts. In addition mice concurrently infected with Mtb had fewer p24Gag-specific IFN-γ-expressing T cells and multifunctional T cells in their spleens. These results suggest that Mtb infection might interfere with the outcome of prospective HIV vaccination in humans.

show abstract

Influenza vaccination for older adults

Cited by 9 publications

References 43 publications

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial

Vaccines for older adults

Mycobacterium tuberculosis Infection Interferes with HIV Vaccination in Mice

Contact Info

Product

Resources

About